Recently, another pathway has been described in a breast cancer model, where CD99-derived agonist ligands inhibit fibronectin-mediated β1 integrin activation, through the SHP2/ERK/PTPN12/FAK1 signaling pathway [30]. The gene discussed is CD99; the disease is breast cancer.